Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 35 of 46

Specific Findings About Adverse Effects

Reported rates of adverse effects are similar between DMARDs and placebo in nearly all published randomized controlled trials.

Methotrexate is associated with more laboratory abnormalities than are other DMARDs. Combination therapy with infliximab and methotrexate is associated with more serious adverse effects and infections than are other DMARDs.

Two publications surveying the world literature identified 66 cases of malignancy in children with JIA treated with TNF-α–blocking DMARDs.

In this effectiveness review, 11 cases of malignancy were identified in more than 4,000 patient reports.